Secondary Outcome(s)
|
Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in HAQ-DI at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 24 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 24]
|
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in SF-36 MCS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in SF-36 Mental Component Scores (MCS) at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in White Blood Cell (WBC) Count at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma-Glutamyl Transpeptidase (GGT) at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 24]
|
Change From Baseline in CDAI Total Score at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Arthritis Pain VAS at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 52]
|
Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in HAQ-DI at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 52]
|
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 24]
|
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 24]
|
Change From Baseline in SF-36 PCS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein-cholesterol at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 52]
|
Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) >=Grade 3 Hematological/Clinical Chemistry Abnormalities for Placebo Switched Arms
[Time Frame: Up to Week 59]
|
Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in Short Form (SF)-36 Physical Component Scores (PCS) at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Change From Baseline in WBC Count at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Van Der Heijde mTSS at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in WBC Count at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Week 12), Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 24]
|
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 52]
|
Number of Participants Achieving ACR/EULAR Remission at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving 20% Improvement in ACR20 at Week 24 (Non-Inferiority Versus Tofacitinib)
[Time Frame: Week 24]
|
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria (ACR50/70) at Week 24 and ACR 20/50/70 at and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) >=Grade 3 Hematological/Clinical Chemistry Abnormalities
[Time Frame: Up to Week 59]
|
Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Placebo Switched Arms
[Time Frame: Baseline (Day 1) and Week 24]
|
Percentage of Participants Achieving ACR20/50/70 at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving DAS28 Erythrocyte Sedimentation Rate (ESR) <=3.2 (DAS28-ESR LDA) at Week 12
[Time Frame: Week 12]
|
Change From Baseline in SF-36 Domain Scores at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in SF-36 MCS at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Less Than or Equal to (<=)10 [CDAI Low Disease Activity (LDA)] at Week 12
[Time Frame: Week 12]
|
Number of Participants With Anti-GSK3196165 Antibodies
[Time Frame: Up to Week 59]
|
Percentage of Participants Achieving a Good/Moderate (European League Against Rheumatism) EULAR Response at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
[Time Frame: Up to Week 59]
|
Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) for Placebo Switched Arms
[Time Frame: Up to Week 59]
|
Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving no Radiographic Progression (Van Der Heijde Modified Total Sharp Scores (mTSS <= 0.5) at Week 12
[Time Frame: Week 12]
|
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Hematology Parameter of Hemoglobin at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 12
[Time Frame: Baseline (Day 1) and Week 12]
|
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1) and Week 52]
|
Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Change From Baseline in SF-36 PCS at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Baseline (Day 1), Week 24 and Week 52]
|
Concentrations of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Autoantibody
[Time Frame: At baseline]
|
Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria (ACR50/70) at Week 12
[Time Frame: Week 12]
|
Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Placebo Switched Arms
[Time Frame: Week 24 and Week 52]
|
Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <=3.2 (DAS28-CRP LDA) at Week 12
[Time Frame: Week 12]
|